Survival Benefit of Palliative Local Treatments and Efficacy of Different Pharmacotherapies in Colorectal Cancer With Lung Metastasis: Results From a Large Retrospective Study

Wang, Zhenghang; Wang, Xicheng; Yuan, Jiajia; Zhang, Xiaotian; Zhou, Jun; Lu, Ming; Liú, Dan; Li, Jian; Shen, Lin

doi:10.1016/j.clcc.2017.12.005

Cited by 33 publications

(37 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Elderly patients have heart, lung and renal dysfunctions due to the immune system growing weaker with age [13]. It is usually questions how and where is the goal.…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, little is known about clinicopathologic features and prognostic factors specific for this older and frail subset of mCRC patients. This is especially true of peripheral neuropathy(CIPN), which is based on Oxaliplatin-associated chemotherapy and is the most frequent cause of complete discontinuation of an otherwise successful therapy [13,14].…”

Section: Discussionmentioning

confidence: 99%

“…This is especially true of peripheral neuropathy (CIPN) due to oxaliplatin-associated chemotherapy. This is the most frequent cause of discontinuation of a beneficial chemotherapy [13,14].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Maintenance Therapy for Elderly Colorectal Cancer Patients with Bevacizumab: Single Center Experience

Orita¹,

Koshiba²,

Kushida³

et al. 2018

Cancer Sci Res

View full text Add to dashboard Cite

Background: Over the past decade, the outcome of treatment with chemotherapy for metastatic colorectal cancer (mCRC) is substantially better, with proven increases survival. However, many patients still suffer significant toxicities, such as peripheral neuropathy. In advanced countries, where most patients with mCRC are older, maintenance therapy is under study with the goal of reducing severe side effects and maintaining quality of life (QOL). Continuation of cytotoxic chemotherapy in the setting of accumulated toxicities is often not feasible, so less toxic drugs are needed over the long-term. Bevacizumab is one option that has low side effects and proven benefit when combined with chemotherapy. This report describes our experience in giving bevacizumab maintenance therapy to 11 older patients with mCRC and reviews maintenance therapy for mCRC. Materials and Methods:Baseline clinical characteristics, pre-specified bevacizumab-related adverse events, and efficacy data were collected from the local patient registry. Approval was provided by the Juntendo University Hospital Institutional Review Board. Results: Eleven patients received maintenance therapy after FOLFOX and/or FOLFIRI regimens for an average of 476 days. Maintenance therapy was instituted due to several side effects from oxaliplatin-based chemotherapy.Side effect included such as peripheral neuropathy and fatigue could reduce during maintenance therapy and get QOL until end stage.Conclusions: Our experience with these 11 patients, demonstrates both prolonged survival as well as maintained QOL. Bevacizumab based maintenance therapy may be considered in elderly patients with mCRC.

show abstract

“…Elderly patients have heart, lung and renal dysfunctions due to the immune system growing weaker with age [13]. It is usually questions how and where is the goal.…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Maintenance Therapy for Elderly Colorectal Cancer Patients with Bevacizumab: Single Center Experience

Orita¹,

Koshiba²,

Kushida³

et al. 2018

Cancer Sci Res

View full text Add to dashboard Cite

show abstract

“…Compared to liver metastases, lung metastases accounted for 32.9% of all metastatic CRCs. [ 106 ] Similarly, rectal cancer also has a higher risk of developing lung metastases compared to colon cancer. [ 107 ] According to the expert consensus on the multidisciplinary treatment of CRC with lung metastases (2019 edition) in China, treatment strategies for patients who initially have resectable lung metastases mainly include R 0 surgery, stereotactic body radiation therapy, and ablation therapy.…”

Section: Surgical Treatmentmentioning

confidence: 99%

Current status of surgical treatment of rectal cancer in China

Yang

Wang

Chen

et al. 2020

Chinese Medical Journal

View full text Add to dashboard Cite

With the changing lifestyle and the acceleration of aging in the Chinese population, the incidence and mortality of colorectal cancer (CRC) have risen in the last decades. On the contrary, the incidence and mortality of CRC have continued to decline in the USA since the 1980s, which is mainly attributed to early screening and standardized diagnosis and treatment. Rectal cancer accounts for the largest proportion of CRC in China, and its treatment regimens are complex. At present, surgical treatment is still the most important treatment for rectal cancer. Since the first Chinese guideline for diagnosis and treatment of CRC was issued in 2010, the fourth version has been revised in 2020. These guidelines have greatly promoted the standardization and internationalization of CRC diagnosis and treatment in China. And with the development of comprehensive treatment methods such as neoadjuvant chemoradiotherapy, targeted therapy, and immunotherapy, the post-operative quality of life and prognosis of patients with rectal cancer have improved. We believe that the inflection point of the rising incidence and mortality of rectal cancer will appear in the near future in China. This article reviewed the current status and research progress on surgical therapy of rectal cancer in China.

show abstract

“…Clinically, CRC with isolated lung metastasis (LM) is less common and is observed in 10-15% of CRC patients [6]. Isolated LM is characterized by the absence of extrapulmonary metastasis [7]. Approximately 35% of CRC patients with LM develop isolated initial tumors, and patients with colon cancer have a lower incidence of initial LM than patients with rectal cancer have [7].…”

Section: Introductionmentioning

confidence: 99%

Genomic profiling of colorectal cancer with isolated lung metastasis

Zhang

Wang

et al. 2020

Cancer Cell Int

View full text Add to dashboard Cite

Background: Metastasis is a major cause of failed colorectal cancer (CRC) treatment. While lung metastasis (LM) is observed in 10-15% of patients with CRC, the genetic mechanisms that cause CRC to metastasize to the lung remain unclear. Methods: In this study, we employed whole exome sequencing (WES) of primary CRC tumors and matched isolated LM lesions to compare their genomic profiles. Comprehensive genomic analyses of five freshly frozen primary tumor lesions, five paired LM lesions, and matched non-cancerous tissues was achieved by WES. Results: An integrated analysis of somatic mutations, somatic copy number alterations, and clonal structures revealed that genomic alterations were present in primary and metastatic CRCs with various levels of discordance, indicating substantial levels of intertumor heterogeneity. Moreover, our results suggest that the founder clone of the primary tumor was responsible for the formation of the metastatic lesion. Additionally, only a few metastasis-specific mutations were identified, suggesting that LM-promoting mutations might be pre-existing in primary tumors. Conclusions: Primary and metastatic CRC show intertumor heterogeneity; however, both lesions were founded by the same clone. These results indicate that malignant clones contributing to disease progression should be identified during the genetic prognosis of cancer metastasis.

show abstract

Survival Benefit of Palliative Local Treatments and Efficacy of Different Pharmacotherapies in Colorectal Cancer With Lung Metastasis: Results From a Large Retrospective Study

Cited by 33 publications

References 33 publications

Maintenance Therapy for Elderly Colorectal Cancer Patients with Bevacizumab: Single Center Experience

Maintenance Therapy for Elderly Colorectal Cancer Patients with Bevacizumab: Single Center Experience

Current status of surgical treatment of rectal cancer in China

Genomic profiling of colorectal cancer with isolated lung metastasis

Contact Info

Product

Resources

About